Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases

Acta Ophthalmologica

Volumn 96, Issue 1, 2018, Pages e1-e9

  Nguyen, Quan Dong ^a   De Falco, Sandro ^b   Behar Cohen, Francine ^c,d   Lam, Wai Ching ^e   Li, Xuri ^f   Reichhart, Nadine ^g   Ricci, Federico ^h   Pluim, Jennifer ⁱ   Li, William W ^j  

^a Ocular Imaging Research and Reading Center   (United States)

^b INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e UNIVERSITY OF TORONTO   (Canada)

^f SUN YAT SEN UNIVERSITY   (China)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

ⁱ Pharmacovigilance and Risk Management   (United States)

^j The Angiogenesis Foundation   (United States)

more..

Author keywords

angiogenesis; diabetic retinopathy; neovascularization; placental growth factor; retina; vascular endothelial growth factor

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PLACENTAL GROWTH FACTOR; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AGE RELATED MACULAR DEGENERATION; CLINICAL OUTCOME; CLINICAL RESEARCH; COMPARATIVE EFFECTIVENESS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EYE DISEASE; GOLD STANDARD; HEART INFARCTION; HUMAN; MICROANGIOPATHY; NONHUMAN; OCULAR NEOVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RETINA CELL; RETINA VEIN OCCLUSION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; VITREOUS BODY; ANIMAL; METABOLISM; RETINA; RETINA NEOVASCULARIZATION;

ANIMALS; CHOROIDAL NEOVASCULARIZATION; DIABETIC RETINOPATHY; HUMANS; PLACENTA GROWTH FACTOR; RETINA; RETINAL NEOVASCULARIZATION;

EID: 85006078289     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.13325     Document Type: Review

References (95)

1. Adams RH & Alitalo K (2007): Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 8: 464–478.
2. Aiello LP, Avery RL, Arrigg PG et al. (1994): Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331: 1480–1487.
3. Autiero M, Luttun A, Tjwa M & Carmeliet P (2003): Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1: 1356–1370.
4. Avery RL, Castellarin AA, Steinle NC et al. (2014): Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol 98: 1636–1641.
5. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR & Mahajan VB (2013): Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156: 15–22.
6. Beaudry P, Hida Y, Udagawa T et al. (2007): Endothelial progenitor cells contribute to accelerated liver regeneration. J Pediatr Surg 42: 1190–1198.
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP & Ianchulev T (2009): Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116: 57–65.
8. Brown DM, Nguyen QD, Marcus DM et al. (2013): Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120: 2013–2022.
9. Brown DM, Schmidt-Erfurth U, Do DV et al. (2015): Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122: 2044–2052.
10. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY & Rubio RG (2010): Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117: 1102–1112.
11. Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY & Rubio RG (2011): Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118: 2041–2049.
12. Campochiaro PA, Clark WL, Boyer DS et al. (2015): Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology 122: 538–544.
13. Cao R, Xue Y, Hedlund EM et al. (2010): VEGFR1-mediated pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci USA 107: 856–861.
14. Cao Y, Arbiser J, D'Amato RJ et al. (2011): Forty-year journey of angiogenesis translational research. Sci Transl Med 3: 114rv3.
15. Carmeliet P, Moons L, Luttun A et al. (2001): Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575–583.
16. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W & Zhu M (2014): Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 121: 188–192.
17. Chen X, Li J, Li M et al. (2013): KH902 suppresses high glucose-induced migration and sprouting of human retinal endothelial cells by blocking VEGF and PlGF. Diabetes Obes Metab 15: 224–233.
18. Cicatiello V, Apicella I, Tudisco L et al. (2015): Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. Oncotarget 6: 10563–10576.
19. Clark WL, Boyer DS, Heier JS et al. (2015): Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology 122: 538–544.
20. Cui JZ, Hinz BJ, Greve MD, Potter MJ, Hornan D, Samad A, To E & Matsubara JA (2003): Expression of neuropilin-1 in choroidal neovascular membranes. Can J Ophthalmol 38: 41–45.
21. De Falco S (2012): The discovery of placenta growth factor and its biological activity. Exp Mol Med 44: 1–9.
22. De Falco S, Gigante B & Persico MG (2002): Structure and function of placental growth factor. Trends Cardiovasc Med 12: 241–246.
23. Deissler HL, Lang GK & Lang GE (2014): Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells. Exp Eye Res 122: 20–31.
24. Falavarjani KG & Nguyen QD (2013): Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27: 787–794.
25. Feeney SA, Simpson DA, Gardiner TA, Boyle C, Jamison P & Stitt AW (2003): Role of vascular endothelial growth factor and placental growth factors during retinal vascular development and hyaloid regression. Invest Ophthalmol Vis Sci 44: 839–847.
26. Ferrara N & Henzel WJ (1989): Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161: 851–858.
27. Fischer C, Jonckx B, Mazzone M et al. (2007): Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463–475.
28. Fischer C, Mazzone M, Jonckx B & Carmeliet P (2008): FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8: 942–956.
29. Gebala V, Collins R, Geudens I, Phng LK & Gerhardt H (2016): Blood flow drives lumen formation by inverse membrane blebbing during angiogenesis in vivo. Nat Cell Biol 18: 443–450.
30. Gelfand MV, Hagan N, Tata A et al. (2014): Neuropilin-1 functions as a VEGFR2 co-receptor to guide developmental angiogenesis independent of ligand binding. Elife 3: e03720.
31. Gibson JM & Gibson SJ (2014): A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. Expert Opin Drug Saf 13: 1259–1270.
32. Gonzalez VH, Boyer DS, Schmidt-Erfurth U et al. (2015): Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. Retina 35: 687–694.
33. Gross JG, Glassman AR, Jampol LM et al. (2015): Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314: 2137–2146.
34. Heier JS, Brown DM, Chong V et al. (2012): Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119: 2537–2548.
35. Heier JS, Clark WL, Boyer DS et al. (2014): Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 121: 1414–1420.
36. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE & Hubbard GB III(2013): Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156: 23–28.
37. Holz FG, Tadayoni R, Beatty S et al. (2015): Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 99: 220–226.
38. Huang H, Shen J & Vinores SA (2011): Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye. PLoS One 6: e21411.
39. Huang H, He J, Johnson D et al. (2015): Deletion of placental growth factor prevents diabetic retinopathy and is associated with Akt activation and HIF1alpha-VEGF pathway inhibition. Diabetes 64: 200–212.
40. Ishihama H, Ohbayashi M, Kurosawa N, Kitsukawa T, Matsuura O, Miyake Y & Muramatsu T (2001): Colocalization of neuropilin-1 and Flk-1 in retinal neovascularization in a mouse model of retinopathy. Invest Ophthalmol Vis Sci 42: 1172–1178.
41. Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H & Ahmed A (1996): Localisation of placenta growth factor (PlGF) in human term placenta. Growth Factors 13: 243–250, color.
42. Khaliq A, Foreman D, Ahmed A, Weich H, Gregor Z, McLeod D & Boulton M (1998): Increased expression of placenta growth factor in proliferative diabetic retinopathy. Lab Invest 78: 109–116.
43. Kitchens JW, Do DV, Boyer DS et al. (2016): Comprehensive review of ocular and systemic safety events with intravitreal aflibercept injection in randomized controlled trials. Ophthalmology 123: 1511–1520.
44. Korobelnik JF, Do DV, Schmidt-Erfurth U et al. (2014): Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121: 2247–2254.
45. Kowalczuk L, Touchard E, Omri S et al. (2011): Placental growth factor contributes to micro-vascular abnormalization and blood-retinal barrier breakdown in diabetic retinopathy. PLoS One 6: e17462.
46. Krause TA, Alex AF, Engel DR, Kurts C & Eter N (2014): VEGF-production by CCR2-dependent macrophages contributes to laser-induced choroidal neovascularization. PLoS One 9: e94313.
47. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J & Freund KB (2013): Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33: 1605–1612.
48. Lanahan A, Zhang X, Fantin A et al. (2013): The neuropilin 1 cytoplasmic domain is required for VEGF-A-dependent arteriogenesis. Dev Cell 25: 156–168.
49. Lassen U, Nielsen DL, Sorensen M et al. (2012): A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours. Br J Cancer 106: 678–684.
50. Lim JI, Spee C, Hangai M, Rocha J, Ying HS, Ryan SJ & Hinton DR (2005): Neuropilin-1 expression by endothelial cells and retinal pigment epithelial cells in choroidal neovascular membranes. Am J Ophthalmol 140: 1044–1050.
51. Luttun A, Tjwa M, Moons L et al. (2002): Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831–840.
52. Malecaze F, Clamens S, Simorre-Pinatel V, Mathis A, Chollet P, Favard C, Bayard F & Plouet J (1994): Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 112: 1476–1482.
53. Mantovani A, Allavena P, Sica A & Balkwill F (2008): Cancer-related inflammation. Nature 454: 436–444.
54. Miki A, Miki K, Ueno S et al. (2010): Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells. J Cell Physiol 224: 262–272.
55. Miller JW, Adamis AP, Shima DT et al. (1994): Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574–584.
56. Mitamura Y, Tashimo A, Nakamura Y, Tagawa H, Ohtsuka K, Mizue Y & Nishihira J (2002): Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care 25: 2352.
57. Miyamoto N, de Kozak Y, Normand N, Courtois Y, Jeanny JC, Benezra D & Behar-Cohen F (2008): PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalmic Res 40: 203–207.
58. Nagy JA, Dvorak AM & Dvorak HF (2007): VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2: 251–275.
59. Nagy JA, Benjamin L, Zeng H, Dvorak AM & Dvorak HF (2008): Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 11: 109–119.
60. Nguyen QD, Brown DM, Marcus DM et al. (2012): Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789–801.
61. Ogura Y, Roider J, Korobelnik JF et al. (2014): Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158: 1032–1038.
62. Otrock ZK, Makarem JA & Shamseddine AI (2007): Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 38: 258–268.
63. Pan Q, Chanthery Y, Liang WC et al. (2007): Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11: 53–67.
64. Papadopoulos N, Martin J, Ruan Q et al. (2012): Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15: 171–185.
65. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW & Hartnett ME (2008): Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 27: 331–371.
66. Plate KH, Breier G, Weich HA & Risau W (1992): Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845–848.
67. Plouet J, Schilling J & Gospodarowicz D (1989): Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 8: 3801–3806.
68. Rakic JM, Lambert V, Devy L et al. (2003): Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44: 3186–3193.
69. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY & Kim RY (2006): Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355: 1419–1431.
70. Roy H, Bhardwaj S & Yla-Herttuala S (2006): Biology of vascular endothelial growth factors. FEBS Lett 580: 2879–2887.
71. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al. (2014): Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121: 193–201.
72. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G & Lelgemann M (2011): Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 95: 308–317.
73. Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M & Loke YK (2012): A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One 7: e42701.
74. Seguin-Greenstein S, Lightman S & Tomkins-Netzer O (2016): A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept. J Ophthalmol 2016: 4095852.
75. Shih SC, Ju M, Liu N & Smith LE (2003): Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity. J Clin Invest 112: 50–57.
76. Shweiki D, Itin A, Soffer D & Keshet E (1992): Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843–845.
77. Spirin KS, Saghizadeh M, Lewin SL, Zardi L, Kenney MC & Ljubimov AV (1999): Basement membrane and growth factor gene expression in normal and diabetic human retinas. Curr Eye Res 18: 490–499.
78. Sulzbacher F, Roberts P, Munk MR, Kaider A, Kroh ME, Sacu S & Schmidt-Erfurth U (2015): Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. Invest Ophthalmol Vis Sci 56: 1158–1167.
79. Takagi H, King GL & Aiello LP (1996): Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45: 1016–1023.
80. Talks JS, Lotery AJ, Ghanchi F et al. (2016): First-Year visual acuity outcomes of providing aflibercept according to the view study protocol for age-related macular degeneration. Ophthalmology 123: 337–343.
81. Tarallo V, Vesci L, Capasso O et al. (2010): A placental growth factor variant unable to recognize vascular endothelial growth factor (VEGF) receptor-1 inhibits VEGF-dependent tumor angiogenesis via heterodimerization. Cancer Res 70: 1804–1813.
82. Tarallo V, Tudisco L & De FS (2011): A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. Am J Cancer Res 1: 265–274.
83. Tarallo V, Bogdanovich S, Hirano Y, Tudisco L, Zentilin L, Giacca M, Ambati J & De FS (2012): Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci 53: 7989–7996.
84. Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N & Adamis AP (1996): Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 114: 964–970.
85. Ueno S, Pease ME, Wersinger DM et al. (2008): Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels. J Cell Physiol 217: 13–22.
86. Van de Veire S, Stalmans I, Heindryckx F et al. (2010): Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 141: 178–190.
87. Wells JA, Glassman AR, Ayala AR et al. (2015): Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372: 1193–1203.
88. Wietecha MS, Cerny WL & DiPietro LA (2013): Mechanisms of vessel regression: toward an understanding of the resolution of angiogenesis. Curr Top Microbiol Immunol 367: 3–32.
89. Wise GN (1956): Retinal neovascularization. Trans Am Ophthalmol Soc 54: 729–826.
90. Witmer AN, Vrensen GF, van Noorden CJ & Schlingemann RO (2003): Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22: 1–29.
91. Wykoff CC, Brown DM, Maldonado ME & Croft DE (2014): Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol 98: 951–955.
92. Yao J, Wu X, Zhuang G et al. (2011): Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci USA 108: 11590–11595.
93. Yonekawa Y, Andreoli C, Miller JB et al. (2013): Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156: 29–35.
94. Yoo SA, Yoon HJ, Kim HS, Chae CB, De FS, Cho CS & Kim WU (2009): Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation: a link between angiogenesis and inflammation. Arthritis Rheum 60: 345–354.
95. Zheng Y, Gu Q & Xu X (2012): Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1. Acta Ophthalmol 90: e512–e523.